Yuan Li, Yunshan Zhou, Jing He, Jinchuan Chen, Hua Zhu, Zhi Yang, Qian Wang, Nan Li
{"title":"用于诊断自身免疫性风湿病的 18F-FDG 和 Al18F-NOTA-FAPI-04 PET/CT 成像的头对头比较。","authors":"Yuan Li, Yunshan Zhou, Jing He, Jinchuan Chen, Hua Zhu, Zhi Yang, Qian Wang, Nan Li","doi":"10.1007/s10067-024-07155-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to determine the performance of radionuclide-labeled fibroblast activation protein inhibitors (Al<sup>18</sup>F-NOTA-FAPI-04) PET/CT in patients with autoimmune rheumatic diseases (ARDs) and compare it with fluorine-18 (<sup>18</sup>F) labeled fluorodeoxyglucose (FDG) imaging.</p><p><strong>Methods: </strong>Fifty-eight participants with ARDs were prospectively enrolled from April 2022 to February 2024 and underwent dual-tracer PET/CT imaging. For both <sup>18</sup>F-FDG and Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT, imaging findings were interpreted and compared. The clinical significance was compared between<sup>18</sup>F-FDG PET/CT and Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging.</p><p><strong>Results: </strong><sup>18</sup>F-FDG imaging was positive in 53 out of 58 cases (91.4%) while Al<sup>18</sup>F-NOTA-FAPI-04 imaging was positive in 55 out of 58 cases (94.8%). Overall positive rate of Al<sup>18</sup>F-NOTA-FAPI-04 imaging was as high as <sup>18</sup>F-FDG imaging (P = 0.625). <sup>18</sup>F-FDG imaging detected more lesions in lymph node, spleen, and bone marrow. Al<sup>18</sup>F-NOTA-FAPI-04 imaging detected more lesions in the lung, muscle, and tendon/ligament. There was no statistical difference of composing ratio of grades of clinical significance between two imaging modalities (χ<sup>2</sup> = 2.875, P = 0.238). The superior rate of Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging was higher than <sup>18</sup>F-FDG imaging (P = 0.020). In subgroup of adult-onset Still's disease, <sup>18</sup>F-FDG imaging showed better performance than Al<sup>18</sup>F-NOTA-FAPI-04 imaging. In most of the other subgroup of ARDs, Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging overperformed <sup>18</sup>F-FDG imaging.</p><p><strong>Conclusion: </strong>Both <sup>18</sup>F-FDG and Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging have excellent sensitivity in ARDs. The detection capabilities of two tracers varied according to the involving organs of ARDs. In most of ARDs except adult-onset Still's disease, Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging overperformed <sup>18</sup>F-FDG imaging. Key Points • <sup>18</sup>F-FDG and Al18F-NOTA-FAPI-04 PET/CT imaging have excellent sensitivity in diagnosing of ARDs. • <sup>18</sup>F-FDG PET/CT imaging detected more lesions in lymph node, spleen, and bone marrow. • <sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging detected more lesions in the lung, muscle, and tendon/ligament. • <sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging overperformed<sup>18</sup>F-FDG in most subgroups of ARDs.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Head to head comparison of <sup>18</sup>F-FDG and Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging used in diagnosis of autoimmune rheumatic diseases.\",\"authors\":\"Yuan Li, Yunshan Zhou, Jing He, Jinchuan Chen, Hua Zhu, Zhi Yang, Qian Wang, Nan Li\",\"doi\":\"10.1007/s10067-024-07155-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>The aim of this study was to determine the performance of radionuclide-labeled fibroblast activation protein inhibitors (Al<sup>18</sup>F-NOTA-FAPI-04) PET/CT in patients with autoimmune rheumatic diseases (ARDs) and compare it with fluorine-18 (<sup>18</sup>F) labeled fluorodeoxyglucose (FDG) imaging.</p><p><strong>Methods: </strong>Fifty-eight participants with ARDs were prospectively enrolled from April 2022 to February 2024 and underwent dual-tracer PET/CT imaging. For both <sup>18</sup>F-FDG and Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT, imaging findings were interpreted and compared. The clinical significance was compared between<sup>18</sup>F-FDG PET/CT and Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging.</p><p><strong>Results: </strong><sup>18</sup>F-FDG imaging was positive in 53 out of 58 cases (91.4%) while Al<sup>18</sup>F-NOTA-FAPI-04 imaging was positive in 55 out of 58 cases (94.8%). Overall positive rate of Al<sup>18</sup>F-NOTA-FAPI-04 imaging was as high as <sup>18</sup>F-FDG imaging (P = 0.625). <sup>18</sup>F-FDG imaging detected more lesions in lymph node, spleen, and bone marrow. Al<sup>18</sup>F-NOTA-FAPI-04 imaging detected more lesions in the lung, muscle, and tendon/ligament. There was no statistical difference of composing ratio of grades of clinical significance between two imaging modalities (χ<sup>2</sup> = 2.875, P = 0.238). The superior rate of Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging was higher than <sup>18</sup>F-FDG imaging (P = 0.020). In subgroup of adult-onset Still's disease, <sup>18</sup>F-FDG imaging showed better performance than Al<sup>18</sup>F-NOTA-FAPI-04 imaging. In most of the other subgroup of ARDs, Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging overperformed <sup>18</sup>F-FDG imaging.</p><p><strong>Conclusion: </strong>Both <sup>18</sup>F-FDG and Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging have excellent sensitivity in ARDs. The detection capabilities of two tracers varied according to the involving organs of ARDs. In most of ARDs except adult-onset Still's disease, Al<sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging overperformed <sup>18</sup>F-FDG imaging. Key Points • <sup>18</sup>F-FDG and Al18F-NOTA-FAPI-04 PET/CT imaging have excellent sensitivity in diagnosing of ARDs. • <sup>18</sup>F-FDG PET/CT imaging detected more lesions in lymph node, spleen, and bone marrow. • <sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging detected more lesions in the lung, muscle, and tendon/ligament. • <sup>18</sup>F-NOTA-FAPI-04 PET/CT imaging overperformed<sup>18</sup>F-FDG in most subgroups of ARDs.</p>\",\"PeriodicalId\":10482,\"journal\":{\"name\":\"Clinical Rheumatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10067-024-07155-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10067-024-07155-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Head to head comparison of 18F-FDG and Al18F-NOTA-FAPI-04 PET/CT imaging used in diagnosis of autoimmune rheumatic diseases.
Objectives: The aim of this study was to determine the performance of radionuclide-labeled fibroblast activation protein inhibitors (Al18F-NOTA-FAPI-04) PET/CT in patients with autoimmune rheumatic diseases (ARDs) and compare it with fluorine-18 (18F) labeled fluorodeoxyglucose (FDG) imaging.
Methods: Fifty-eight participants with ARDs were prospectively enrolled from April 2022 to February 2024 and underwent dual-tracer PET/CT imaging. For both 18F-FDG and Al18F-NOTA-FAPI-04 PET/CT, imaging findings were interpreted and compared. The clinical significance was compared between18F-FDG PET/CT and Al18F-NOTA-FAPI-04 PET/CT imaging.
Results: 18F-FDG imaging was positive in 53 out of 58 cases (91.4%) while Al18F-NOTA-FAPI-04 imaging was positive in 55 out of 58 cases (94.8%). Overall positive rate of Al18F-NOTA-FAPI-04 imaging was as high as 18F-FDG imaging (P = 0.625). 18F-FDG imaging detected more lesions in lymph node, spleen, and bone marrow. Al18F-NOTA-FAPI-04 imaging detected more lesions in the lung, muscle, and tendon/ligament. There was no statistical difference of composing ratio of grades of clinical significance between two imaging modalities (χ2 = 2.875, P = 0.238). The superior rate of Al18F-NOTA-FAPI-04 PET/CT imaging was higher than 18F-FDG imaging (P = 0.020). In subgroup of adult-onset Still's disease, 18F-FDG imaging showed better performance than Al18F-NOTA-FAPI-04 imaging. In most of the other subgroup of ARDs, Al18F-NOTA-FAPI-04 PET/CT imaging overperformed 18F-FDG imaging.
Conclusion: Both 18F-FDG and Al18F-NOTA-FAPI-04 PET/CT imaging have excellent sensitivity in ARDs. The detection capabilities of two tracers varied according to the involving organs of ARDs. In most of ARDs except adult-onset Still's disease, Al18F-NOTA-FAPI-04 PET/CT imaging overperformed 18F-FDG imaging. Key Points • 18F-FDG and Al18F-NOTA-FAPI-04 PET/CT imaging have excellent sensitivity in diagnosing of ARDs. • 18F-FDG PET/CT imaging detected more lesions in lymph node, spleen, and bone marrow. • 18F-NOTA-FAPI-04 PET/CT imaging detected more lesions in the lung, muscle, and tendon/ligament. • 18F-NOTA-FAPI-04 PET/CT imaging overperformed18F-FDG in most subgroups of ARDs.
期刊介绍：
Clinical Rheumatology is an international English-language journal devoted to publishing original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level.
The journal succeeds Acta Rheumatologica Belgica, originally founded in 1945 as the official journal of the Belgian Rheumatology Society. Clinical Rheumatology aims to cover all modern trends in clinical and experimental research as well as the management and evaluation of diagnostic and treatment procedures connected with the inflammatory, immunologic, metabolic, genetic and degenerative soft and hard connective tissue diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
